Medicine Overview of Onriva Plus Bexicap 50mcg+110mcg Capsule
Onriva Plus Bexicap is used for the treatment of chronic obstructive pulmonary disorder (a lung disorder in which the flow of air to the lungs is blocked). It helps in relaxing the muscles of the air passages and making it easier to breathe. It relieves coughing, wheezing and feeling short of breath.
Your doctor will tell you how often you need to use your inhaler. The effect of this medicine may be noticeable after a few days but will only reach its maximum after a few weeks. This medicine must be used regularly to be effective, so go on taking it even if you don’t have any symptoms. That means it’s doing its job. If you stop taking it your COPD may get worse. This medicine should not be used to relieve sudden shortness of breath. To get the benefit from this medicine you need to make sure you get your inhaler technique right, otherwise, it Does not work as well.
The most common side effects are indigestion, high blood pressure, nasopharyngitis (inflammation of the throat and nasal passages), chest pain, fever, sore throat, cough, headache, dizziness, inflammation of the nose, and sinus inflammation. If you get there, don’t stop taking it but do talk to your doctor. You can prevent some of these symptoms by rinsing your mouth and throat with water or brushing your teeth after using your inhaler. There are other, rarer side effects which can be serious. Talk to your doctor if you’re worried about them.
- Chronic obstructive pulmonary disease (COPD)
- Indigestion
- High blood pressure
- Nasopharyngitis (inflammation of the throat and nasal passages)
- Chest pain
- Fever
- Urinary retention
- Sore throat
- Cough
- Headache
- Dizziness
- Allergic reaction
- Increased glucose level in blood
- Inflammation of the nose
- Sinus inflammation
- Urinary tract infection
-
Onriva Plus Bexicap is a combination of two medicines that makes breathing easier for patients with chronic obstructive pulmonary disease (COPD).
-
This medicine is for inhalation only. The tablet should not be swallowed.
-
It should be taken at the same time each day.
-
It does not work right away and should not be used to relieve sudden breathing problems.
-
Take the first dose of this medicine under medical supervision as it may cause wheezing or tightening of the airways (bronchospasm) immediately after using.
-
Dry mouth may occur as a side effect. Frequent mouth rinses, good oral hygiene, increased water intake and sugarless candy may help.
-
Your doctor may regularly monitor your blood potassium levels as low oxygen levels in the blood (hypoxia) and COPD medicines such as Onriva Plus Bexicap can lower potassium levels in blood.
For inhalation use only. The capsules must not be swallowed.
Adult
Chronic Obstructive Pulmonary Disease (COPD)
Inhale 1 cap with inhaler once daily.
Hepatic Impairment: This can be used at the recommended dose in patients with mild and moderate hepatic impairment. There are no data available for the use of Indacaterol + Glycopyrronium Breezhaler in patients with severe hepatic impairment, therefore caution should be observed in these patients.
Safety and efficacy not established
Hypersensitivity to indacaterol, glycopyrronium or to any of the excipients of Indacaterol + Glycopyrronium. All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication Indacaterol/glycopyrrolate is not indicated for the treatment of asthma
Use in children: This should not be used in patients <18 years.
Glycopyrronium: Long-acting muscarinic antagonist (LAMA); often referred to as an anticholinergic; produces bronchodilation by inhibiting acetylcholine’s effect on muscarinic receptors in the airway smooth muscle
Indacaterol: Long-acting beta2-agonist (LABA); stimulates intracellular adenyl cyclase, causing conversion of ATP to cyclic AMP; increased cyclic AMP levels cause relaxation of bronchial smooth muscle
Concomitant use w/ long-acting beta-agonists or long-acting muscarinic antagonists. Not for the treatment of asthma. Immediately discontinue use if hypersensitivity & paradoxical bronchospasm occurs. Narrow-angle glaucoma, urinary retention, CV disorders (CAD, acute MI, cardiac arrhythmia, HTN), convulsive disorders or thyrotoxicosis, severe renal impairment; hypokalaemia; hyperglycaemia. Pregnancy & lactation.
1-10%
Nasopharyngitis (4.1%),Hypertension (2%),Back pain (1.8%),Oropharyngeal pain (1.6%)
Decreases levodopa effects. Effects may be enhanced by using drugs with antimuscarinic properties or MAOIs concurrently. May antagonise the GI effects of cisapride, metoclopramide and dompeidone.
Potentially Fatal: IV admin in the presence of cyclopropane anesth can result in ventricular arrhythmias.
Reviews
Clear filtersThere are no reviews yet.